|
Patient characteristics, complications, and secondary surgical/endovascular interventions |
|
Total number of patients | 59 |
Male versus female patients | 55 (93.2%) | 4 (6.8%) |
Emergent versus elective EVAR | 3 (5%) | 56 (95%) |
Mean age at the date of implantation | 70 yrs | (41–83 yrs) |
Mean body mass index | 28 ± 4.3 kg/m2. |
Observation period terminated by non-EVAR related death | 8 (13.6%) |
Lost to follow-up | 2 (3.4%) |
Compliance versus noncompliance with the surveillance schedule | 36 (61%) | 23 (39%) |
Open surgical correction procedures | 2 (3.4%) |
(i) Aortorenal bypass grafting for renal artery occlusion | 1 (1.7%) |
(ii) Explantation of a migrated stent graft and implantation of a bifurcated vascular graft | 1 (1.7%) |
Long-term corticosteroid treatment for suspected periprosthetic inflammatory reaction | 1 (1.7%) |
Endoleak (median persistence 222 days (IQR 66–787 days)) | 22 (37.3%) |
Primary endoleak (i.e., occurring within 30 days from EVAR), all classified as type II | 19 (32.2%) |
(i) Permanent | 4 (21.0%) |
(ii) Treated by endovascular intervention | 3 (15.8%) |
(iii) Spontaneous resolution (81% resolved during the first year post-EVAR) | 12 (63.2%) |
Secondary endoleak (i.e., occurring more than 30 days from EVAR) | 3 (5%) |
(i) Type II endoleak diagnosed 7 weeks after EVAR, death for nonaneurysm related causes | 1 (1.7%) |
(ii) Type II endoleak diagnosed 15 weeks after EVAR, spontaneous shrinkage of the aneurysm sac, no interventional or surgical correction but close surveillance | 1 (1.7%) |
(iii) Type I endoleak resulting from graft dislocation 3 years after EVAR, treated by open surgical repair | 1 (1.7%) |
Secondary endovascular procedures | 11 in 9 patients |
(i) Minimum/maximum period from EVAR to secondary endovascular procedure | 1 day/3.3 years |
(ii) Fibrinolysis, angioplasty, and/or stent angioplasty for graft limb occlusion | 5/11 |
(iii) Embolization of endoleaks | 3/11 |
(iv) Stent angioplasty for renal artery stenosis | 2/11 |
(v) Stent angioplasty for iliac artery stenosis | 1/11 |
|